About: Arginase inhibition by (−)-Epicatechin reverses endothelial cell aging

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Arginase inhibition by (−)-Epicatechin reverses endothelial cell aging Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Arginase inhibition by (−)-Epicatechin reverses endothelial cell aging
Creator	Ceballos, Guillermo Villarreal, Francisco Castillo, Carmen Garate-Carrillo, Alejandra Guevara, Gustavo Mendoza-Lorenzo, Patricia Najera, Nayelli Navarrete-Yañez, Viridiana Ortiz-Flores, Miguel Ortiz-Vilchis, Pilar Ramirez-Sanchez, Israel Rubio-Gayosso, Ivan De, Casco Hidalgo, Del Luis, San Miron, Diaz Muratt Bustamante-Pozo, Moises Plan, Nacional Politecnico, Instituto Ramirez, Israel Tomas, Santo
Source	Elsevier; Medline; PMC
abstract	Endothelial dysfunction (EnD) occurs with aging and endothelial nitric oxide (NO) production by NO synthase (NOS) can be impaired. Low NO levels have been linked to increased arginase (Ar) activity as Ar competes with NOS for L-arginine. The inhibition of Ar activity can reverse EnD and (−)-epicatechin (Epi) inhibits myocardial Ar activity. In this study, through in silico modeling we demonstrate that Epi interacts with Ar similarly to its inhibitor Norvaline (Norv). Using in vitro and in vivo models of aging, we examined Epi and Norv-inhibition of Ar activity and its endothelium-protective effects. Bovine coronary artery endothelial cells (BCAEC) were treated with Norv (10 μM), Epi (1 μM) or the combination (Epi + Norv) for 48 h. Ar activity increased in aged BCAEC, with decreased NO generation. Treatment decreased Ar activity to levels seen in young cells. Epi and Epi + Norv decreased nitrosylated Ar levels by ∼25% in aged cells with lower oxidative stress (∼25%) (dihydroethidium) levels. In aged cells, Epi and Epi + Norv restored the eNOS monomer/dimer ratio, protein expression levels and NO production to those of young cells. Furthermore, using 18 month old rats 15 days of treatment with either Epi (1 mg/kg), Norv (10 mg/kg) or combo, decreased hypertension and improved aorta vasorelaxation to acetylcholine, blood NO levels and tetra/dihydribiopterin ratios in cultured rat aortic endothelial cells. In conclusion, results provide evidence that inhibiting Ar with Epi reverses aged-related loss of eNOS function and improves vascular function through the modulation of Ar and eNOS protein levels and activity.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1016/j.ejphar.2020.173442
bibo:pmid	32795514
has license	no-cc
sha1sum (hex)	5d80ef2e868ddabcd7145a09a885a680945bad26
schema:url	https://doi.org/10.1016/j.ejphar.2020.173442
resource representing a document's title	Arginase inhibition by (−)-Epicatechin reverses endothelial cell aging
has PubMed Central identifier	PMC7418791
has PubMed identifier	32795514
schema:publication	Eur J Pharmacol
resource representing a document's body	covid:5d80ef2e868ddabcd7145a09a885a680945bad26#body_text
is schema:about of	named entity 'activity' named entity 'reduction' named entity 'arginase' named entity 'endothelial cell' named entity 'vasodilatory' named entity 'fluorescent' named entity 'eNOS' named entity 'P<0.05' named entity 'nitric oxide' named entity 'centrifuged' named entity 'eNOS' named entity 'phosphorylation' named entity 'sports supplements' named entity 'COVID-19 disease' named entity 'P<0.05' named entity 'protein' named entity 'effects of aging' named entity 'acetylcholine' named entity 'Protein' named entity 'Cardiovascular diseases' named entity 'vasodilatory' named entity 'spectrophotometer' named entity 'eNOS' named entity 'upregulate' named entity 'supernatant' named entity 'BioTek' named entity 'endothelial function' named entity 'fluorometer' named entity 'phosphatase inhibitor' named entity 'age-related' named entity 'antibody' named entity 'mitogen' named entity 'vasodilatory' named entity 'interact' named entity '8.1' named entity 'P<0.05' named entity 'PBS' named entity 'age-related' named entity 'endothelium' named entity 'Discovery Studio' named entity 'centrifuged' named entity 'phospho' named entity 'Discovery Studio' named entity 'acetylcholine' named entity 'oxidative stress' named entity 'mmol/l' named entity 'aortas' named entity 'BH4' named entity 'antibiotic-antimycotic' named entity 'hypertension' named entity 'Nitrosylation' named entity 'aorta' named entity 'Homogenates' named entity '0.01' named entity 'BH4' named entity 'eNOS' named entity 'endothelial cells' named entity 'superoxide' named entity 'estrogen receptor' named entity 'van der Waals' named entity 'nitrotyrosine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software